(Q73260818)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Enhanced anti-proliferative activity of the combination of tamoxifen plus HER-2-neu antibody (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference

L M Witters

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R Kumar

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

V M Chinchilli

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A Lipton

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 January 1997

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

Breast Cancer Research and Treatment

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

1-5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9116313%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1023/a:1005798224288

2 November 2019

exact match

0 references

cites work

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

William L. McGuire Memorial Symposium. The role of erbB2 signal transduction pathways in human breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

HER-2/neu oncogene protein and prognosis in breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

c-erbB-2 oncoprotein expression in primary human tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Epidermal growth factor receptor (EGFr) as a marker for poor prognosis in node-negative breast cancer patients: Neu and tamoxifen failure

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021

High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1005798224288

7 January 2021